FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC
$SNDX
Biotechnology: Pharmaceutical Preparations
Health Care
New Drug Application (NDA): 218944
Company: SYNDAX PHARMACEUTICALS INC
Company: SYNDAX PHARMACEUTICALS INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| REVUFORJ | REVUMENIB | 25MG | TABLET | Prescription | None | No | No |
| REVUFORJ | REVUMENIB | 110MG | TABLET | Prescription | None | No | No |
| REVUFORJ | REVUMENIB | 160MG | TABLET | Prescription | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 11/15/2024 | ORIG-1 | Approval | Type 1 - New Molecular Entity | PRIORITY |
Label (PDF)
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 11/15/2024 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf |